by Shoot To Thrill Media | Oct 21, 2025 | Alzheimer’s Disease, Cognitive Decline, Uncategorized
Medical Review: Dr. Gerald Mastaw, MD – Board-Certified Physician
Last Updated: October 2025
What Is Alzheimer’s Disease?
Alzheimer’s disease (AD) is the most common cause of dementia, a progressive condition that affects memory, reasoning, and daily function. It begins subtly — with mild forgetfulness and disorientation — and gradually impacts independence, communication, and overall quality of life.
Cognitive decline may also result from aging, vascular issues, or brain injury, but Alzheimer’s remains the leading form of degenerative dementia worldwide.
Common Signs of Alzheimer’s and Cognitive Decline
- Persistent memory loss disrupting daily activities
- Difficulty solving problems or performing familiar tasks
- Disorientation about time or place
- Mood or behavioral changes
- Declining judgment or decision-making ability
Although there is currently no cure, early detection and proactive management can slow progression and preserve quality of life.
Traditional Approaches to Treatment
Conventional Alzheimer’s care focuses on symptom management rather than reversing the disease process. Common interventions include:
- Medications: such as donepezil or memantine to temporarily enhance memory or alertness
- Lifestyle modifications: brain exercises, healthy diet, physical activity, and social engagement
- Therapy and support: occupational therapy, caregiver education, and structured routines
- Managing co-conditions: like hypertension or diabetes to support brain health
While these strategies can improve daily function and comfort, they do not repair damaged neurons or prevent future decline.
Regenerative Medicine and Brain Health
Regenerative medicine represents an emerging research frontier focused on repairing or protecting neural tissue, addressing the root causes of neurodegeneration rather than symptoms alone.
Among the most studied are umbilical cord tissue-derived mesenchymal stem cells (UCT-MSCs), which may help:
- Reduce neuroinflammation linked to disease progression
- Support neuronal repair and synaptic regeneration
- Enhance blood flow and nutrient delivery to the brain
- Promote overall cognitive resilience and mood regulation
⚠️ Important:
Stem cell and exosome therapies for Alzheimer’s or cognitive decline are experimental and not FDA-approved.
Current research focuses on safety, dosage, and potential neuroprotective effects.
Recent Clinical Studies on Regenerative Medicine for Alzheimer’s Disease
2025 – Phase 2a Trial: Laromestrocel (Lomecel-B) in Mild Alzheimer’s Disease
Title: Study Published in Nature Medicine Shows Promising Results in Alzheimer’s Disease – Supports the Development of ProTrans at NextCell
Source: NextCell / Nature Medicine – Read Study
Summary:
This Phase 2a double-blind trial enrolled 49 patients with mild Alzheimer’s. Participants received multiple IV infusions of allogeneic mesenchymal stem cells (laromestrocel/Lomecel-B) or placebo over four months.
Results showed improved cognitive scores, slower brain atrophy, and better daily function in the MSC group compared to placebo after 39 weeks. The treatment was well-tolerated, with no serious adverse events reported.
2025 – Nature Medicine Phase 2a Study on Laromestrocel
Title: Allogeneic Mesenchymal Stem Cell Therapy with Laromestrocel in Mild Alzheimer’s Disease: A Randomized Controlled Phase 2a Trial
Journal: Nature Medicine – Read Study
Summary:
This landmark study confirmed that repeated IV MSC infusions were safe and slowed cognitive decline. Patients receiving stem cell therapy demonstrated significantly higher MoCA scores and less brain shrinkage than placebo.
Researchers concluded the therapy “shows disease-modifying potential warranting larger, longer-term trials.”
2024 – Advanced Alzheimer’s Case Report
Title: A Severe Alzheimer’s Disease Patient Improved by Intravenous Mesenchymal Stem Cell Transplant
Journal: Frontiers in Aging Neuroscience – Read Study
Summary:
A single-patient case report documented notable improvements in memory, behavior, and daily functioning following three monthly IV MSC infusions.
The patient regained the ability to recognize family members, follow commands, and perform self-care. Although anecdotal, this report supports the feasibility and safety of repeated stem cell infusions for advanced AD.
2022 – Umbilical Cord MSCs for Vascular Dementia
Title: A Clinical Research of 11 Cases of Human Umbilical Cord MSCs for Curing Senile Vascular Dementia
Journal: Transplant Immunology – PubMed
Summary:
Eleven elderly patients with vascular dementia received three IV infusions of UCT-MSCs.
Cognitive test scores (MMSE) and daily-living ability (Barthel Index) improved significantly — from moderate dementia levels to near-normal ranges over three months.
No serious adverse events occurred, supporting excellent safety and possible benefit in vascular-related cognitive decline.
2021 – Direct Brain Injection Trial (Phase I)
Title: Intracerebroventricular Injection of Human Umbilical Cord Blood MSCs in Patients with Alzheimer’s Disease Dementia
Journal: Alzheimer’s Research & Therapy – Read Study
Summary:
Nine Alzheimer’s patients received intracerebroventricular injections of cord-blood-derived MSCs.
The procedure was feasible and safe, with only brief, mild fever as a side effect. This trial laid the foundation for exploring whether localized brain delivery can more effectively support cognitive function.
Is Regenerative Medicine Right for You or a Loved One?
If you or a family member is facing memory loss or cognitive decline, early evaluation is key. Regenerative medicine may one day complement standard treatments by targeting underlying inflammation and neuronal loss.
Before considering such therapies:
- Consult a qualified neurologist or regenerative medicine physician
- Review clinical research and FDA guidance on investigational use
- Understand that results vary by individual and disease stage
- Set realistic expectations — these therapies remain experimental
At Stemedix, our mission is to provide science-based education and individualized guidance. We follow evidence-informed, transparent protocols and partner with board-certified specialists to help patients explore their options responsibly.
Medical Disclaimer
This page is for educational purposes only and does not constitute medical advice.
Stem cell or exosome therapies for Alzheimer’s disease or cognitive decline are not FDA-approved.
Individual results may vary. Always consult your healthcare provider before considering any medical procedure.
References
- NextCell Pharma / Nature Medicine. ProTrans Phase 2a Alzheimer’s Study, 2025. Link
- Kim H. et al. Allogeneic MSC Therapy with Laromestrocel in Mild Alzheimer’s Disease. Nature Medicine, 2025. Full Text
- Wang L. et al. A Severe Alzheimer’s Disease Patient Improved by IV MSC Transplant. Front. Aging Neurosci., 2024. Full Text
- Zhou J. et al. Human Umbilical Cord MSCs for Senile Vascular Dementia. Transplant Immunology, 2022. PubMed
- Kim J. et al. Intracerebroventricular Injection of Cord-Blood MSCs in Alzheimer’s Disease. Alzheimers Res Ther., 2021. Full Text
Contact us today to learn more and take the next step toward a brighter, more independent future.
Search our blog page to learn more: https://stemedix.com/blog/
by admin | Jul 29, 2025 | Alzheimer’s Disease, Cognitive Decline, Mesenchymal Stem Cells, Regenerative Medicine, Stem Cell Research, Stem Cell Therapy
Alzheimer’s disease (AD) is the most common cause of dementia, gradually destroying memory, learning, and functional independence. Current FDA-approved drugs such as donepezil, rivastigmine, galantamine, and memantine provide limited symptomatic relief but do not slow the progression of neuronal loss. Antibody therapies that target amyloid plaques have shown inconsistent clinical outcomes. As a result, researchers are pursuing biological therapies that act on multiple disease pathways simultaneously. Mesenchymal stem/stromal cells (MSCs) are one of the most promising candidates under investigation.
As part of this review, Regmi et al. focus on different clinical and preclinical studies using MSC as a therapy for treating AD, their outcomes, limitations and the strategies to potentiate their clinical translation.
Disease Progression and Pathophysiology
AD develops slowly, progressing from a preclinical phase with no visible symptoms to mild cognitive impairment and eventually to dementia. Early in the disease, abnormal accumulation of amyloid-beta and metabolic dysfunction begin to disrupt neuronal communication. Over time, inflammation, oxidative stress, and tau protein abnormalities lead to widespread neuronal death. Most cases are diagnosed after age 65 (late-onset AD), while a smaller number of familial and early-onset forms appear earlier and are often linked to genetic mutations in the amyloid precursor protein or presenilin genes.
Rationale for Stem Cell Therapy
Stem cell-based interventions aim to repair or protect the brain rather than simply alleviate symptoms. By influencing cellular and immune processes, stem cells have the potential to address core mechanisms of AD, including inflammation, oxidative injury, and synaptic loss. Mesenchymal stem/stromal cells are particularly attractive because they are relatively easy to obtain from bone marrow, adipose tissue, or umbilical cord sources. They have low immunogenicity, strong anti-inflammatory and regenerative potential, and do not present the ethical or oncogenic risks associated with embryonic stem cells.
Mechanisms of Action of Mesenchymal Stem Cells
MSCs exert therapeutic effects primarily through their secreted factors rather than direct cell replacement. They release a complex mixture of cytokines, growth factors, and microRNAs that modulate inflammation, promote neuronal survival, and enhance the brain’s self-repair mechanisms. Key mechanisms include the suppression of pro-inflammatory immune responses, stimulation of microglial clearance of amyloid-beta, reduction of tau hyperphosphorylation, and protection of neurons from oxidative and apoptotic stress. MSCs also secrete neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), which support neurogenesis and synaptic plasticity.
Evidence from Preclinical Research
In animal models of AD, MSC transplantation has consistently reduced amyloid burden, decreased inflammation, and improved cognitive performance. Studies using MSCs from bone marrow, adipose tissue, placenta, and umbilical cord sources have demonstrated enhanced memory retention, reduced oxidative stress, and improved neural connectivity. The therapeutic mechanism appears to vary with disease stage: in early disease, MSCs enhance amyloid clearance and regulate tau processing; in later stages, their effects are more strongly associated with antioxidant and anti-inflammatory actions.
Findings from Clinical Trials
Early human trials suggest that MSC therapy is safe and feasible. Patients receiving MSCs through intracerebral, intravenous, or intrathecal routes have generally tolerated treatment without serious adverse effects. Some studies have shown modest improvements in cognitive function and inflammatory biomarkers, while others report minimal change. The variation in results likely reflects differences in cell source, dose, route of administration, and disease stage. Continued large-scale, standardized clinical studies are needed to determine optimal protocols and confirm therapeutic efficacy.
Role of MSC-Derived Exosomes and Extracellular Vesicles
Much of the therapeutic activity of MSCs is now attributed to the extracellular vesicles (EVs) they release. These nanoscale structures, including exosomes, contain proteins, enzymes, and microRNAs capable of crossing the blood-brain barrier. EVs can replicate many of the beneficial effects of MSCs while minimizing risks such as immune rejection or tumor formation. Research has shown that MSC-derived exosomes can reduce amyloid-beta levels, suppress inflammation, and improve cognitive outcomes in AD models. MicroRNAs such as miR-21, miR-29b, miR-29c-3p, and miR-455-3p appear to regulate pathways that protect neurons, clear toxic proteins, and enhance synaptic health.
Regulation of Microglial Function
According to the authors, microglia play a dual role in the AD brain—clearing debris and pathogens under normal conditions but driving chronic inflammation when persistently activated. MSCs help reprogram microglia toward a neuroprotective, anti-inflammatory phenotype. They secrete molecules such as soluble intercellular adhesion molecule-1 (sICAM-1), CX3CL1, and growth differentiation factor-15 (GDF-15) that enhance the clearance of amyloid-beta and suppress pro-inflammatory cytokines. By promoting a balance between microglial activation and resolution, MSCs reduce oxidative stress and protect surrounding neurons from further injury.
Challenges in Clinical Translation
Despite encouraging findings, MSC-based therapy faces several technical and biological challenges. Intravenously delivered MSCs are often trapped in the lungs, limiting brain exposure. The blood-brain barrier restricts cell migration, and outcomes vary based on patient age, disease severity, and individual immune responses. Standardization across studies remains a critical barrier: cell sources, preparation methods, and dosing regimens differ widely. Consistent, reproducible manufacturing practices are necessary for large-scale clinical application.
Emerging Strategies to Enhance Efficacy
Researchers are exploring innovative approaches to overcome delivery and efficacy challenges. Direct injection into brain tissue or cerebrospinal fluid can increase local concentrations of MSCs, while focused ultrasound can temporarily open the blood-brain barrier to facilitate targeted delivery. Magnetic targeting using nanoparticle-labeled MSCs and external magnets may also improve cell homing. Preconditioning MSCs with agents such as melatonin or cannabidiol enhances their survival and therapeutic potency. Genetic engineering approaches are being tested to overexpress beneficial molecules such as BDNF, VEGF, and Wnt3a. In parallel, MSC-derived exosomes are being developed as a cell-free therapeutic platform, combining many of the benefits of MSCs with improved safety and scalability.
Matching Therapy to Disease Stage
Treatment effectiveness may depend on when MSCs are introduced. Early in the disease, the goal is to enhance clearance of amyloid and preserve synapses, whereas in later stages the focus shifts toward reducing inflammation, protecting surviving neurons, and maintaining cognitive function. Regmi et al. report that future clinical protocols will likely tailor treatment approaches to biomarkers and disease progression to maximize benefit for individual patients.
Current Clinical Considerations
MSCs for Alzheimer’s disease remain in the experimental phase. Early studies indicate safety and biological activity, but definitive evidence of long-term clinical benefit is lacking. Patients considering participation in MSC trials should ensure that studies are properly regulated and that the source, preparation, and administration of cells or exosomes are clearly described. Understanding how the intervention aligns with individual disease stage and biomarkers is essential to setting realistic expectations.
Future Directions and Outlook
Mesenchymal stem/stromal cells represent a multifaceted therapeutic avenue for Alzheimer’s disease, addressing inflammation, oxidative damage, neuronal loss, and vascular dysfunction simultaneously.
According to the authors, the next phase of research must focus on standardizing cell preparation, identifying optimal delivery routes, and designing rigorous, well-powered clinical trials. Continued advances in focused ultrasound, genetic enhancement, and exosome technology are expected to strengthen the feasibility and impact of this approach.
Advancing Toward Clinical Application
Although mesenchymal stem cell therapy is not yet a proven treatment for Alzheimer’s disease, the authors indicate that the growing body of preclinical and early clinical evidence suggests significant therapeutic promise. By promoting neuroprotection, immune regulation, and tissue repair, MSCs and their derivatives could form the foundation of next-generation regenerative strategies for neurodegenerative conditions.
With further research and careful clinical translation, MSC-based therapies may one day help preserve cognitive function and improve quality of life for individuals affected by Alzheimer’s disease.
Source: Regmi S, Liu DD, Shen M, Kevadiya BD, Ganguly A, Primavera R, Chetty S, Yarani R, Thakor AS. Mesenchymal stromal cells for the treatment of Alzheimer’s disease: Strategies and limitations. Front Mol Neurosci. 2022 Oct 6;15:1011225. doi: 10.3389/fnmol.2022.1011225. PMID: 36277497; PMCID: PMC9584646.
by admin | May 8, 2025 | Alzheimer’s Disease, Regenerative Medicine, Stem Cell Research, Stem Cell Therapy
Alzheimer’s disease affects millions of people around the world, but women seem to carry a larger burden. In fact, nearly two-thirds of all Alzheimer’s cases are found in women. While it’s true that women tend to live longer than men – and age is the greatest risk factor for Alzheimer’s – researchers now believe that’s not the whole story.
Recent studies have revealed a much more complex picture involving brain biology, hormones, genetics, and even social and cultural experiences. One key moment in a woman’s life – menopause – might be a critical piece of the puzzle.
Dr. Roberta Brinton, a neuroscientist at the University of Arizona, has spent over three decades researching why women are more vulnerable to Alzheimer’s. Her interest in the subject began when she met a woman named Dr. Rowena Ansbacher, a clinical trial participant with early Alzheimer’s. After a heartfelt conversation, Brinton witnessed the sharp impact of memory loss when Ansbacher no longer recognized her moments later. That experience motivated Brinton to focus her career on understanding the female brain’s unique vulnerability to cognitive decline.
The Menopause Connection
As women reach midlife, they begin to experience menopause – a natural process that marks the end of menstrual cycles and a significant drop in estrogen levels. While estrogen is best known for its role in reproduction, it also plays a major part in how the brain functions. Estrogen helps brain cells use glucose for energy, supporting memory, attention, and overall cognitive function.
When estrogen levels fall, the brain struggles to get the energy it needs. Dr. Brinton’s research shows that in response, brain cells may start using alternate energy sources – including the brain’s own white matter, a fatty tissue that supports communication between brain cells. This “self-cannibalization” process can damage brain structures and potentially raise the risk of Alzheimer’s.
Brain Imaging Reveals More
Dr. Lisa Mosconi, a neuroscientist at Weill Cornell Medical College, has used brain scans to compare men’s and women’s brains during midlife. Her research shows that women between ages 40 and 65 have:
- 22% less brain glucose metabolism (less energy available for brain activity)
- 11% less white matter
- 30% more Alzheimer’s-related plaques compared to men the same age
Mosconi emphasizes that Alzheimer’s doesn’t suddenly appear in old age – it likely begins decades earlier, around the same time many women enter menopause. These early changes may go unnoticed but could signal increased risk later in life.
Not Every Woman Develops Alzheimer’s – So What Else Plays a Role?
While every woman goes through menopause, not all develop Alzheimer’s. Researchers believe that a mix of genetic, hormonal, and lifestyle factors shape a woman’s risk.
For example, women with metabolic syndrome – marked by high blood sugar, high triglycerides, or blood pressure problems – are more likely to develop Alzheimer’s after menopause. Risk is even higher for women who carry a specific gene called APOE4, which is strongly linked to Alzheimer’s.
Fortunately, midlife may offer a window of opportunity to lower that risk. By managing conditions like high blood pressure and metabolic syndrome during menopause, women may be able to support long-term brain health.
The Role of Hormone Therapy in Brain Health
One potential strategy for supporting women’s brain health during menopause is hormone replacement therapy (HRT), which restores estrogen levels. In a large review study, Dr. Brinton found:
- Women using HRT for 1–3 years had a 40% lower risk of developing Alzheimer’s or Parkinson’s.
- Women using HRT for 3–6 years saw a 60% risk reduction.
- Women on HRT for more than 6 years experienced an 80% lower risk.
These findings are promising, but HRT is not without controversy. Some studies suggest it could increase dementia risk, particularly if started later in life. Timing may be everything: starting HRT during menopause might protect the brain, while starting it years later may not offer the same benefits – or could even be harmful.
Experts, including Dr. Michelle Mielke from Wake Forest University, agree that HRT can be safe for short-term use to relieve menopausal symptoms. However, they caution that it shouldn’t be used solely to prevent Alzheimer’s, especially without discussing individual risk factors with a physician.
Estrogen Exposure Over a Lifetime Matters
Estrogen’s protective effects seem to depend not only on menopause but also on how long a woman is exposed to the hormone throughout her life. A 2020 study of 15,000 women found:
- Women with shorter reproductive spans (less than 34 years between first period and menopause) had a 20% higher risk of dementia.
- Women who started menstruating at 16 or older had a 31% higher Alzheimer’s risk than those who started around age 13.
- Women who had their ovaries and uterus removed had an even higher risk.
Interestingly, the study also found that women with three or more children had a 12% lower Alzheimer’s risk, possibly due to social support and caregiving benefits that come with having a larger family.
Social and Cultural Factors: Beyond Biology
While hormones and genetics matter, social and cultural experiences also shape brain health. Around the world, Alzheimer’s rates in women vary by country. In some places, such as England and Australia, dementia has become the leading cause of death for women. These patterns may reflect not just biology, but life history – including war, famine, education access, and societal gender roles.
For example, in post-World War II Europe, older women often faced severe stress, limited education, and fewer job opportunities. These early-life disadvantages can affect cognitive function decades later.
Women with higher education levels tend to have better “cognitive reserve” – the brain’s ability to compensate for damage. Research shows that women who work in mentally demanding jobs experience slower memory decline as they age. Yet, historically, many women were denied equal access to education and career advancement, reducing their opportunity to build this cognitive reserve.
The Role of Structural Sexism
Newer research is also uncovering how societal-level discrimination – known as structural sexism – affects brain health. A study led by Justina Avila-Rieger at Columbia University analyzed 21,000 women and compared their memory performance to the level of sexism in the state where they were born. Women who grew up in states with higher levels of sexism – such as fewer women in leadership, larger wage gaps, and less workplace equality – experienced faster memory decline after age 65.
Black women were disproportionately affected, suggesting that discrimination based on both gender and race takes a heavier toll on brain health. The stress of lifelong inequality can lead to chronic inflammation, which may damage brain cells and increase dementia risk over time.
“We tend to focus on biology,” Avila-Rieger says, “but changing the social environment may have an even bigger impact on women’s health.”
A Call for Better Research
Historically, women have been underrepresented in medical research – even though they are more likely to get Alzheimer’s. Until recently, most dementia studies were not designed to explore sex differences, and many clinical trials still don’t include enough female participants. As a result, many Alzheimer’s symptoms in women may go undiagnosed or misinterpreted.
For example, women tend to perform better on common memory tests, which can mask early signs of cognitive decline. When they do report symptoms, doctors may dismiss them as stress, anxiety, or depression.
Meanwhile, research funding also falls short. In 2019, just 12% of NIH Alzheimer’s research funding went to women-focused projects. A nonprofit analysis found that doubling investment in female-focused dementia research would ultimately save nearly $1 billion by reducing healthcare costs and time spent in nursing homes.
Moving Toward a More Inclusive Approach
Experts say we need a broader approach to understanding and preventing Alzheimer’s in women. That means:
- Supporting hormone balance during midlife through healthy lifestyle choices- and, in some cases, HRT under medical supervision
- Managing chronic health conditions like high blood pressure, diabetes, and metabolic syndrome
- Reducing gender-based stressors and addressing structural inequalities
- Increasing women’s access to education and cognitively stimulating careers
- Prioritizing research that includes sex and gender differences
Dr. Mosconi, who now leads a $50 million global program focused on Alzheimer’s in women, believes we’re just scratching the surface. “We owe women centuries of research,” she says.
A New Chapter in Alzheimer’s Prevention
Alzheimer’s disease is not simply a disease of old age – it may begin years, even decades, before symptoms appear. For women, especially, the transition into menopause could be an important turning point. By paying attention to hormonal health, lifestyle risks, and the effects of social and cultural inequality, we may be able to change the course of Alzheimer’s and improve outcomes for future generations of women.
Source: Moutinho, S. Women twice as likely to develop Alzheimer’s disease as men — but scientists do not know why. Nat Med 31, 704–707 (2025). https://doi.org/10.1038/s41591-025-03564-3
by admin | Apr 17, 2025 | ALS, Alzheimer’s Disease, Neurodegenerative Diseases, Parkinson's Disease, Stem Cell Research, Stem Cell Therapy
Neurodegenerative diseases like Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) are among the most challenging medical conditions to treat. These disorders involve the gradual breakdown and loss of neurons in specific areas of the nervous system, leading to symptoms such as memory loss, paralysis, and impaired movement or cognition.
Despite decades of research and billions of dollars in clinical trials, researchers have yet to find a cure for these conditions, and even effective treatments remain limited. As a result, neurodegenerative diseases place a significant emotional, physical, and economic burden on individuals, families, and healthcare systems worldwide.
In this review, Sivandzade et al. summarize the current knowledge of stem-cell-based therapies in neurodegenerative diseases and the recent advances in this field.
The Potential of Stem Cells in Treating Neurodegenerative Disorders
In recent years, regenerative medicine, particularly stem cell therapy, has emerged as an exciting new frontier in the treatment of neurodegenerative diseases. Stem cells have the remarkable ability to become various types of specialized cells in the body. In the context of neurodegenerative diseases, they may be able to repair damaged tissue, replace lost neurons, or create a healthier environment in the brain or spinal cord that helps preserve existing cells.
This unique potential has led researchers to explore whether stem cells could help slow disease progression, reduce symptoms, or even restore lost function in patients affected with these conditions.
Stem Cell Therapy Approaches in Neurological Disorders
Stem cell therapy strategies for neurodegenerative diseases typically fall into two main approaches. The first involves directly replacing the specific types of neurons that are lost during the disease process. For example, researchers aim to generate dopamine-producing neurons for patients with PD or restore damaged motor neurons in people with ALS. The second approach focuses on environmental enrichment, where stem cells are used to support the body’s own repair mechanisms. According to the authors, this could involve delivering neuroprotective growth factors like brain-derived neurotrophic factor (BDNF) or glial cell line-derived neurotrophic factor (GDNF), which help nourish and protect surviving neurons.
Recent research has also explored combining both strategies – using stem cells to replace lost cells while simultaneously enhancing the surrounding environment.
Stem Cell Therapy for Parkinson’s Disease
In Parkinson’s disease, the main issue is the gradual loss of dopamine-producing neurons in a part of the brain called the substantia nigra. This loss leads to symptoms like tremors, muscle rigidity, and slowed movement, usually appearing in people between their 50s and 70s.
Current treatments focus on increasing dopamine levels or using deep brain stimulation to control symptoms. While helpful, these options do not stop or reverse the underlying neuron loss. Stem cell therapy offers a promising alternative by aiming to replace the lost dopamine neurons or protect those that remain.
Recent studies have used embryonic stem cells (ESCs) to produce new dopamine-producing cells that can be transplanted into animal models of PD. These cells have shown the ability to migrate to damaged areas and improve motor function. However, ESCs come with ethical concerns and a risk of tumor formation, which has limited their use in human trials.
Mesenchymal stem cells (MSCs) have also shown potential in PD animal models by helping rebuild damaged dopamine nerve networks. Additionally, induced pluripotent stem cells (iPSCs) – adult cells reprogrammed to act like embryonic stem cells – have recently gained attention because they can be used to generate personalized dopamine-producing neurons without the ethical concerns associated with ESCs. These iPSC-derived neurons have shown promising results in animal models, surviving and integrating into the brain while improving motor symptoms.
Stem Cell Therapy for Alzheimer’s Disease
For patients with Alzheimer’s disease, the situation is more complex. AD is the most common neurodegenerative disease, affecting over 5 million Americans. It leads to memory loss, confusion, impaired judgment, and eventually complete cognitive decline. The disease is marked by the buildup of two harmful proteins in the brain: amyloid-beta, which forms plaques outside neurons, and tau, which forms complex tangles inside them. These protein abnormalities disrupt communication between brain cells and eventually cause them to die. Current medications focus on improving symptoms and slowing progression, but they do not reverse the damage.
Stem cell therapy for AD focuses on restoring lost neurons and improving the brain’s ability to function and heal. Studies using human neural stem cells in animal models of Alzheimer’s have shown that these cells can improve learning and memory, possibly by enhancing synaptic plasticity and increasing the production of proteins involved in cognitive function.
However, challenges remain, including understanding how these stem cells exert their effects and controlling the formation of unwanted cell types. Researchers are currently exploring the use of nerve growth factor (NGF) in combination with stem cells to protect existing neurons and encourage the growth of new ones.
NGF gene therapy has shown promise in early trials and may help amplify the positive effects of stem cell treatment.
Stem Cell Therapy for ALS (Amyotrophic Lateral Sclerosis)
Amyotrophic lateral sclerosis, or ALS, is another devastating condition in which motor neurons in the brain and spinal cord gradually die, leading to muscle weakness, paralysis, and ultimately death, typically within a few years of diagnosis. Most cases are sporadic and occur without a clear genetic cause, though some cases are linked to inherited gene mutations. Because multiple mechanisms may contribute to the disease, including protein misfolding, oxidative stress, and inflammation, it has been extremely difficult to find effective treatments.
Stem cell research in ALS is still in the early stages, but it holds potential. The goal is not necessarily to replace the lost motor neurons – which is extremely difficult – but rather to create a supportive environment that preserves the neurons that remain and slows disease progression.
Some clinical trials have tested the use of MSCs and neural stem cells (NSCs) injected directly into the spinal cord. Results from these early studies suggest that the treatments are safe and may help stabilize function in some patients. In animal models, stem cell transplants have been shown to reduce inflammation, promote motor neuron survival, and improve muscle strength.
As with other neurodegenerative diseases, the success of stem cell therapy in ALS will likely depend on a deeper understanding of disease mechanisms and finding the best ways to target and deliver treatment.
The Future of Stem Cell Therapy for Neurodegenerative Diseases
While stem cell therapy is not yet a viable cure for neurodegenerative diseases, Sivandzade et al. believe it represents one of the most promising paths forward. The ability to regenerate or repair damaged tissue offers hope where traditional therapies have fallen short. As research continues to advance, more clinical trials are likely to explore the safety and effectiveness of these treatments, along with better methods for personalizing therapies and improving the delivery of stem cells to targeted areas within the nervous system.
Source: Sivandzade F, Cucullo L. Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview. Int J Mol Sci. 2021 Feb 22;22(4):2153. doi: 10.3390/ijms22042153. PMID: 33671500; PMCID: PMC7926761.
by admin | Feb 15, 2024 | Peptides, ALS, Alzheimer’s Disease
Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) are two of the more common neurodegenerative diseases, with nearly seven million people in the US living with the conditions in 2023. While AD is more prevalent than ALS, they are both characterized by the progressive loss of specific neurons and glial cells in the central nervous system.
Research has demonstrated that the onset and progression of neurodegenerative diseases appear to be delayed or improved by the application of neurotrophic factors and that the derived peptide factors from these neurotrophic factors have been found to potentially restore neuronal function, improve behavioral deficits, and prolong their survival.
In this review, Ciesler and Sari review the role of trophic peptides in the improvement of AD and ALS with the goal of developing a better understanding of potential therapies for these neurodegenerative diseases.
While neurodegenerative diseases, including AD and ALS, are well documented to result in debilitating loss of memory and motor function, respectively, the specific mechanisms of action in these diseases are yet to be fully understood. However, research has found that the potential underlying mechanisms can be divided into two categories. The first, which is unique to each neurodegenerative disease, is a specific trigger that activates cell death machinery and the second, which appears to be universal among neurodegenerative diseases, is a directorial process to complete death of a neuron.
While there are currently no effective drugs for the treatment of neurodegenerative diseases, treatments of the symptoms associated with neurodegenerative diseases include neuroprotective factors, encompassing neurotrophins, and neuroprotective peptides. The authors focus this review on NAP peptide derived from activity neuroprotective protein and ADNF-9 peptide derived from activity-dependent neurotrophic factor (ADNF); both of these peptides have been shown to enhance cell survival and outgrowth of dendrites in the form of D-acid analogues.
NAP’s parent protein, ADNP, is essential for brain development and was found to protect neurons against severe oxidative stress. Studies examining NAP have found them to protect against neurotoxins while not affecting cell division. Considering these findings, NAP is now in phase II clinical trials with a primary focus on AD-related cognitive impairment. Additional studies are also evaluating the effects of NAP in ALS models associated with cytoskeletal dysfunction. NAP has been found to extend life span in ALS mouse models when administered prior to disease onset.
ADNF is released in response to vasoactive intestinal peptide that protects neurons from tetrodotoxin-induced cell death and is suggested to be essential for neuronal survival. ADNF-9 showed greater prevention of cell death associated with stress than other ADNF peptides; additional studies demonstrate that ADNF-9 suppressed SOD-1-mediated cell death. While prolonged survival of ALS mouse model was reported to be marginal, the authors highlight that the study did provide insight into a possible treatment for ALS.
The authors also highlight colivelin, a hybrid synthetic peptide of ANDF-9 and humanin, which was found to provide neuroprotection against AD-related memory loss and have a more potent neuroprotective effect than humanin and ADNF-9 when they are tested alone against neurotoxicity.
Ciesler and Sari conclude that in contrast to neurotrophic factors these trophic peptides have the ability to cross the blood-brain barrier for efficacy and have potential for future treatment of ALS and AD.
Source: “Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic ….” 8 Apr. 2013, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686488/.
by Stemedix | Dec 11, 2023 | Stem Cell Therapy, Alzheimer’s Disease, Autoimmune, Health Awareness, Osteoarthritis, Parkinson's Disease
Treatment of injuries and damage to organs and other tissues as a result of the aging process or conditions has often relied on managing symptoms. By offering painkillers and steroids, healthcare providers can keep you more comfortable, but they are not targeting the cause of the problem. This means you have to keep relying on medications. One option more people are exploring is regenerative medicine, also known as stem cell therapy. This type of regenerative medicine offers the chance to treat the underlying cause of the issue so that you can achieve lasting relief. In this article we will discuss how does stem cell therapy work?
What Is Stem Cell Therapy?
Stem cell therapy utilizes stem cells, which are those that create specialized cells. They can regenerate damaged or dying cells. Although you retain stem cells throughout your life, the aging process can make them less effective. This aging can lead to injuries that don’t heal completely, causing chronic pain and many other problems.
The goal of stem cell therapy is to amplify your body’s natural healing processes. To do this, it relies on stem cells.
In stem cell therapy, these cells are often harvested from the patient’s own body or from donors, and then administered to the affected area or systemically. The goal is to encourage tissue regeneration, repair damaged cells, and promote healing. Stem cells can differentiate into the specific cell types needed to replace or repair damaged tissues, making them a promising treatment for a wide range of conditions.
Stem cell therapy has shown potential in treating conditions such as heart disease, neurological disorders (e.g., Parkinson’s and Alzheimer’s disease), autoimmune conditions, and orthopedic injuries.
Benefits of Stem Cell Therapy
Stem cell therapy is a less invasive option than many other therapies. It requires the removal of stem cells from fat or bone marrow and then the injection of the prepared stem cells at the site of the damage. This not only makes it a viable option for those who can’t undergo surgery, but it also means the recovery process is shorter.
Another benefit of stem cell therapy is that it helps reduce inflammation. When you get injured, your body responds by causing inflammation to prevent the spread of damaging agents while also helping remove pathogens and cell debris. Inflammation also helps prepare the area for the repair process.
In some instances, however, inflammation doesn’t go away, leading to chronic pain. Inflammation also makes it more difficult for the wound to heal because the area is not receiving enough blood.
Stem cell therapy helps reduce this inflammation, allowing oxygen and nutrients to make their way to the damaged area. Less inflammation results in less pain.
Stem cell therapy is also a quick procedure. It can be done as an outpatient option, and it doesn’t require general anesthesia. Because most people benefit from adult stem cells, the procedure also avoids the need to worry about rejections or allergic reactions.
What to Expect from the Stem Cell Therapy Procedure
The first thing you will need to do is reach out to your healthcare provider to see if you are a good candidate for stem cell therapy. Your provider will go through your medical history to see which types of stem cells you can benefit the most from. The kind of condition or injury you have will impact this choice.
If you’re using your own stem cells, your healthcare provider will collect a sample from your bone marrow or fat. They then process them in a laboratory to isolate and concentrate them. In some cases, the process can involve centrifugation, filtering, and other options to help collect the highest number of stem cells.
The next step is receiving the stem cells, which can take place intravenously, with an injection, as well as other administration techniques.
After you receive the stem cells, your healthcare provider will monitor you to ensure there are no complications. They will also schedule follow-up phone calls to monitor how you are doing post-treatment.
Most people can get right back to their daily activities with some minimal post-treatment guidelines without having to worry about long recovery times.
Available Stem Cell Treatments
How does stem cell therapy work & what are the available treatments? Stem cells can help treat a variety of conditions. It’s helpful in treating cartilage regeneration and osteoarthritis because the stem cells can differentiate into chondrocytes, which are cells that maintain cartilage.
It’s also an option that can help with scar reduction and wound healing. For this procedure, stem cells derived from fat cells are a good option. They can help with tissue regeneration, potentially leading to healing chronic wounds and even the prevention of scarring.
Stem cell therapy is also a good choice for neurodegenerative issues. It can help replace neurons and provide neuroprotective benefits, potentially leading to slowing down the disease’s progression.
Stem cell therapy may also target ligament and tendon injuries, which are common in people who are very active. This type of therapy can help speed up the recovery process and might even be able to prevent the development of chronic pain issues that can affect mobility.
Another way stem cell therapy is able to help is by treating autoimmune diseases. Most autoimmune diseases are impacted by inflammation, so an option like stem cell therapy, which helps reduce swelling, can be helpful.
Choosing Stem Cell Therapy for Lasting Results
Stem cell therapy offers hope for the treatment of many types of conditions. By targeting the cause of pain and chronic injuries, like inflammation, you can avoid relying solely on pain medications, which only mask symptoms. Stem cell therapy makes it possible to have available options to help manage orthopedic injuries, neurodegenerative conditions, and much more.
If you want to learn more about how does stem cell therapy work and not sure whether stem cell therapy is a good option for your needs, speak with a regenerative medicine specialist. They can let you know if you are a good candidate.
St. Petersburg, Florida
